Inhibrx Biosciences, Inc. Working Capital to Net Assets Ratio
Inhibrx Biosciences, Inc. working capital to net assets ratio. Inhibrx Biosciences, Inc. (INBX) has a Working Capital to Net Assets ratio of -688.5% as of March 2026. Working capital of $144.83 Million (current assets of $171.34 Million minus current liabilities of $26.51 Million) is measured against net assets of $-21.04 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Inhibrx Biosciences, Inc. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Inhibrx Biosciences, Inc. (2016–2025)
Working capital to net assets ratio of Inhibrx Biosciences, Inc. from 2016 to 2025. This chart shows how Inhibrx Biosciences, Inc.'s Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at -688.5%, reflecting working capital of $144.83 Million against net assets of $-21.04 Million USD. See how many days can Inhibrx Biosciences, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Inhibrx Biosciences, Inc. Working Capital to Net Assets Ratio by Year (2016–2025)
Inhibrx Biosciences, Inc. working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Inhibrx Biosciences, Inc. from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Inhibrx Biosciences, Inc. total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1239.0% | $99.03 Million | $7.99 Million | $132.83 Million | $33.80 Million | ▲ +1149.4 pp |
| 2024 | 89.6% | $119.67 Million | $133.58 Million | $160.40 Million | $40.73 Million | ▼ -459.9 pp |
| 2023 | 549.5% | $239.05 Million | $43.50 Million | $295.36 Million | $56.31 Million | ▲ +113.9 pp |
| 2022 | 435.6% | $252.92 Million | $58.06 Million | $280.49 Million | $27.58 Million | ▲ +212.9 pp |
| 2021 | 222.7% | $116.66 Million | $52.38 Million | $139.11 Million | $22.45 Million | ▲ +89.2 pp |
| 2020 | 133.5% | $100.77 Million | $75.47 Million | $132.17 Million | $31.40 Million | ▲ +128.2 pp |
| 2019 | 5.4% | $-5.01 Million | $-93.57 Million | $15.56 Million | $20.57 Million | ▼ -12.9 pp |
| 2018 | 18.3% | $-10.53 Million | $-57.64 Million | $5.66 Million | $16.18 Million | ▲ +47.3 pp |
| 2017 | -29.1% | $6.52 Million | $-22.42 Million | $15.44 Million | $8.92 Million | ▼ -1250.1 pp |
| 2016 | 1221.0% | $15.13 Million | $1.24 Million | $20.41 Million | $5.28 Million | — |